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Abstract
Inherently disparate cell growth and division, which are intimately coupled through a delicate 
network of intracellular and extracellular signaling, require ribosomal biogenesis. A number of 
events imparting instability to ribosomal biogenesis can cause nucleolar stress. In response to this 
stress, several ribosomal proteins bind to MDM2 and block MDM2-mediated p53 ubiquitination 
and degradation, resulting in p53-dependent cell cycle arrest. By doing so, the ribosomal proteins 
play a crucial role in connecting deregulated cell growth with inhibition of cell division. The 
ribosomal protein-MDM2-p53 signaling pathway provides a molecular switch that may constitute 
a surveillance network monitoring the integrity of ribosomal biogenesis.
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Introduction
Cell growth (increase in cell size) and cell division (increase in cell number) are two 
separable yet interconnected aspects of cell behavior in all organisms (Conlon and Raff, 
1999). Cell growth is dominant and rate limiting for cell division (Hartwell, 1971). Blocking 
cell growth of cultured mammalian cells by reagents that inhibit ribosomal biogenesis leads 
to arrest of the cell cycle, usually in the G1 phase (Pardee, 1989). Deregulation of the 
molecular mechanisms controlling cell growth results in cells of altered size and leads to 
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developmental errors and a variety of pathological conditions, including cancer (Ruggero 
and Pandolfi, 2003).
It is clear that mutations in genes involved in cell division control often contribute to cancer 
development, and one prominent example is the p53 tumor suppressor. In response to 
cellular stress, p53 is activated to induce cell cycle arrest, senescence or apoptosis. 
Mutations in p53 inactivating p53’s function are frequently found in both familial and 
sporadic human cancers. More than 50% of human cancers harbor mutations in TP53; in 
most of the remaining cancers, the p53 pathway is otherwise inactivated, such as through 
overproduction of the p53 inhibitor MDM2 (murine double minute 2, and also HDM2 for its 
human ortholog) (Toledo and Wahl, 2006). While disruption of normal cell cycle control is 
an established route to cancer, it is more controversial whether an increase in cell growth on 
its own can initiate or promote cancer development (Ruggero and Pandolfi, 2003). Overall, 
the mechanisms that link cell growth with cell division are poorly understood (Sulic et al., 
2005b). However, recent studies began to offer some clues for associating the MDM2-p53 
feedback loop with the sophisticated mechanisms involving ribosomal biogenesis.
The MDM2-p53 feedback loop is regulated in response to a multitude of cytotoxic and 
genotoxic stressors. One of these stressors is called nucleolar stress (a.k.a. ribosomal stress) 
(Rubbi and Milner, 2003). In principle, Ribosome biogenesis is an essential cellular process 
that involves three fundamental steps: coordinated expression of ribosomal RNA (rRNA) 
and ribosomal proteins (RPs), processing of rRNA, and assembly of the 40S and 60S 
ribosome subunits in the nucleolus (Perry, 2007). The 40S and 60S subunits are then 
exported from the nucleolus, through the nucleoplasm, into the cytoplasm for 80S Ribosome 
assembly and protein synthesis (Perry, 2007). Perturbation of any step in this process is 
thought to lead to nucleolar stress, triggering specific binding of several RPs to MDM2, 
which inhibits MDM2’s E3 ubiquitin ligase function toward p53, leading to p53 stabilization 
and activation (Lindstrom et al., 2007a). For instance, expression of a dominant negative 
mutant of Bop1 involved in rRNA processing can inhibit ribosomal biogenesis and elicit p53 
activation (Pestov et al., 2001). Likewise, reduced production of individual RPs can also 
prompt p53 activation. In vivo inactivation of RPS6 activates a p53-dependent checkpoint 
response in thymocytes (Sulic et al., 2005a) or in embryonic fibroblast cells during 
gastrulation (Panic et al., 2006). Similar to the mammalian system, deficiency of several RPs 
in zebrafish also initiates p53-dependent cell growth arrest and apoptosis (Chakraborty et al., 
2009; Danilova et al., 2008). Hence, these findings suggest an important role for the 
nucleolus as a cellular stress sensor in addition to as the workshop for ribosomal biogenesis. 
They also place p53 as a key molecule in the center of the signaling pathway sensing 
nucleolar stress and ribosomal malfunction. This review aims to illustrate recent progress 
toward understanding this newly acknowledged, yet under-studied, RP-MDM2-p53 
signaling pathway [Readers are referred to recent reviews for other extraribosomal functions 
of RPs (Warner and McIntosh, 2009), and downstream functions (Vousden and Prives, 
2009) and regulations (Kruse and Gu, 2009) of p53].
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The ribosomal protein-MDM2-p53 pathway
In order to better illustrate the RP-MDM2-p53 pathway, it is necessary to briefly revisit 
what we have learned regarding the MDM2-p53 feedback loop and its regulation in response 
to cellular stresses. MDM2 regulates p53 primarily in two ways: (i) MDM2 binds directly to 
p53, thereby “masking” p53’s transactivation domain from access to the basal 
transcriptional machinery (Oliner et al., 1993), and (ii) MDM2 acts as an E3 ubiquitin ligase 
for p53, mediating the conjugation of ubiquitins to p53 and subsequent proteasomal 
degradation (Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997). Because MDM2 
itself is a transcriptional target of p53 (Barak et al., 1993; Wu et al., 1993) and deletion of 
Tp53 completely rescues the lethality of Mdm2 knockout mice (Jones et al., 1995; Luna et 
al., 1995), the primary physiological function of MDM2 is thus to serve as a negative 
feedback ”knot” for p53, and therefore unhitching this MDM2 “knot” becomes critical for 
p53 activation by various stresses.
Increasing evidence has supported the notion that various stresses can activate distinct 
cellular signaling pathways that lead to the suppression of MDM2 activity and activation of 
p53 (Vogelstein et al., 2000; Vousden and Lu, 2002). For instance, DNA damage caused by 
genotoxic chemicals and ionizing or ultraviolet radiation triggers the activation of the ATM-
Chk2 or ATR-Chk1 kinase cascades that leads to phosphorylation of both MDM2 and p53, 
blocking their functional or physical interactions (Appella and Anderson, 2001; Prives, 
1998). Also, biological and oncogenic signals, such as viral infection or over expression of 
cellular oncogenes, induce the expression of the tumor suppressor ARF, which in turn binds 
to MDM2 and inhibits its activity (Sherr, 2006; Zhang and Xiong, 2001). Moreover, 
different types of stress have been shown to trigger a number of posttranslational 
modifications, including acetylation, sumoylation, methylation and neddylation, of p53 
and/or MDM2 resulting in p53 activation [reviewed by (Brooks and Gu, 2003; Dai et al., 
2006a; Huang and Berger, 2008; Melchior and Hengst, 2002; Prives and Manley, 2001)].
Recently, a new type of stress signal generated by disrupting ribosomal biogenesis and 
mediated by several RPs has been shown to inhibit MDM2 and activate p53. Ribosomal 
biogenesis can be disrupted by serum starvation, depletion of nucleotides, agents such as 
Actinomycin D, 5-Fluorouracil (5-FU), malfunction of nucleolar proteins involving in 
ribosome biogenesis (such as the dominant negative mutant Bop1) (Pestov et al., 2001), 
inhibition of B23 (a.k.a. nucleophosmin, NPM) activity by ARF (Itahana et al., 2003), and 
reduction of RPS6 (Fumagalli et al., 2009; Volarevic et al., 2000); all of these have been 
shown to generate nucleolar stress that signals to p53. This allows cells to halt proliferation 
under unhealthy and poor ribosomal biogenesis conditions. Although MDM2 was previously 
shown to interact with 5S rRNA and RPL5 (Marechal et al., 1994), the functional meaning 
of the interaction had not been realized until recently when several RPs, including RPL11 
(Lohrum et al., 2003; Zhang et al., 2003), RPL23 (Dai et al., 2004; Jin et al., 2004), and 
RPL5 (Dai and Lu, 2004) were found to activate p53 through their interactions with MDM2.
Previously, RPL5 was shown to participate in MDM2 nuclear export (Roth et al., 1998). It 
was thought that the p53-MDM2 complex might “hitch a ride” on the Ribosome for 
cytoplasmic degradation of p53 (Sherr and Weber, 2000), and p53 accumulation after 
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nucleolar stress was due to its failure to undergo nucleolus-dependent export and 
degradation (Rubbi and Milner, 2003). Later studies identified a direct interaction between 
MDM2 and RPs in response to Actinomycin D induced nucleolar stress, providing the first 
potential molecular mechanism for the nucleolar stress-p53 signaling pathway. Actinomycin 
D, a commonly used drug for human cancers (da Rocha et al., 2001), inhibits transcription 
catalyzed by RNA polymerases (RNA Pol) I, II and III at high concentrations (e.g. >30 nM), 
but it selectively inhibits RNA Pol-I-dependent transcription and hence rRNA production 
and ribosomal biogenesis at low concentrations (e.g. <10 nM) (Iapalucci-Espinoza and 
Franze-Fernandez, 1979; Perry and Kelley, 1970). Treating cells with either a lower dose of 
Actinomycin D or serum starvation inhibits ribosome assembly and consequently releases 
free RPs from the nucleolus to the nucleoplasm (Scheer and Hock, 1999). In response to 
nucleolar stress induced by a low dose of Actinomycin D (5 nM) (Dai and Lu, 2004; Dai et 
al., 2004; Jin et al., 2004) and 5-Fluorouracil (Gilkes et al., 2006; Sun et al., 2007), by serum 
depletion and contact inhibition (Bhat et al., 2004), by mycophenolic acid (MPA)-mediated 
depletion of GTP (Sun et al., 2008), or by interfering with nucleolar function via ectopic 
overexpression of nucleostemin (Dai et al., 2008), there is an increased binding of RPL5, 
RPL11, and RPL23 to MDM2. This binding inhibits MDM2’s E3 ligase function, resulting 
in p53 accumulation and activation. In addition to the three RPs, RPS7 (Chen et al., 2007; 
Zhu et al., 2009) and RPL26 (Ofir-Rosenfeld et al., 2008) have also been shown to interact 
with MDM2. The consequence of the RPS7-MDM2 interaction resembles that of the 
aforementioned three RPs in terms of their binding to MDM2 and activation of p53. 
However, surprising findings from a latest study show that MDMX can facilitate RPS7 
suppression of MDM2 and that RPS7 itself is a substrate for MDM2 ubiquitination. Thus, it 
is proposed that RPS7 acts as both effector and affector of MDM2 (Zhu et al., 2009).
The interaction of RPL26 with MDM2 appears to perform a different function. RPL26 was 
found to increase the translational rate of p53 mRNA by binding to its 5′ untranslated region 
(UTR) (Takagi et al., 2005) and, in this case, MDM2 acts as a ubiquitin E3 ligase for 
ubiquitylation and degradation of RPL26, hence inhibiting p53 translation (Ofir-Rosenfeld 
et al., 2008). Recently, an RPS27-like protein (RPS27L) was identified as a direct p53 
transcriptional target (He and Sun, 2007) and also thought to activate p53 by repressing 
MDM2 activity (personal communication with Y. Sun). Altogether, these findings indicate 
that RPs could play a pivotal role in p53 response to nucleolar stress (Figure. 1).
Multiple ribosomal players
Ribosomal biogenesis consumes a major part of cellular energy and resources and plays a 
key role in the life cycle of a cell (Conlon and Raff, 1999; Neufeld and Edgar, 1998; 
Warner, 1999) and thus is strictly monitored in the cell. Previous studies have been 
concentrated on how changes of proliferation lead to alteration of Ribosome production 
(Pyronnet and Sonenberg, 2001), but less attention has been paid to how alterations of 
ribosomal biogenesis may influence cell proliferation. As discussed above, recent studies 
using mammalian systems have begun to reveal the nucleolar stress-RP-MDM2-p53 
signaling pathway and to unfold the role of this pathway in coordinating inhibition of cell 
growth with cell cycle arrest.
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To monitor the status of cell growth and communicate it with cell division, both are very 
complex and sophisticated cell functions, it is not surprise for the cell to employ multiple 
RPs to regulate the MDM2-p53 feedback loop. Why are multiple RPs necessary? Before 
discussing this, it is necessary to briefly describe MDM2’s functional domains. MDM2 
contains three conserved regions: an N-terminal p53 binding domain, a central acidic region 
encompassing a C4 zinc finger, and a C-terminal RING domain conferring the E3 ligase 
activity. The importance of the central acidic region and the C4 zinc finger for mediating 
MDM2 ubiquitination and degradation of p53 has been elegantly demonstrated by a domain-
swapping experiment between MDM2 and its homolog MDMX (a.k.a. MDM4) (Kawai et 
al., 2003; Meulmeester et al., 2003). This notion is also underscored by the finding that ARF 
binds to this region to suppress MDM2 activity (Argentini et al., 2001; Kawai et al., 2003; 
Meulmeester et al., 2003). Importantly, these findings also provide a basis for how binding 
of the RPs to MDM2 may interfere with MDM2’s inhibition of p53 function.
Like ARF (Argentini et al., 2001; Kawai et al., 2003; Meulmeester et al., 2003), RPL5, 
RPL11, and RPL23 all bind to the central acidic region of MDM2 in an apparently similar 
but non-identical manner (Dai et al., 2004). Detailed analysis of these bindings reveals that 
these RPs require specific domains for efficient MDM2 binding. For example, the MDM2 
C4 zinc finger is critical for its binding to RPL5 and RPL11, as the zinc finger mutant 
MDM2C305F cannot bind either one, but is not required for RPL23 binding (Dai et al., 
2006b; Lindstrom et al., 2007b). Interestingly, a slightly different C4 zinc finger mutant, 
MDM2C305S, fails to bind RPL11, but was still capable of interacting with RPL5 and RPL23 
(Gilkes et al., 2006). Whether RPL11 binds directly to the C4 zinc finger or whether the zinc 
finger only provides structural stability allowing MDM2 to bind to RPL11 remains unclear. 
Nevertheless, these studies suggest that the RPs, though interacting with the same MDM2 
central acidic domain, have specific sequence requirements for binding. Surprisingly, these 
MDM2-interacting RPs have not been found to bind to MDMX (Gilkes et al., 2006; Jin et 
al., 2006), implying that fundamental structural differences exist between MDM2 and 
MDMX even though both contain a similar central acidic domain and C4 zinc finger.
It is still puzzling why RPL11’s ability to bind MDM2 relies so heavily on the MDM2 C4 
zinc finger. Some clues may arise from the structural features of this domain, which belongs 
to a class of zinc fingers known as RanBP2/NZF with a defined consensus sequence X(4)-
W-X-C-X(2- 4)-C-X(3)-N-X(6)-C-X(2)-C-X(5), where “X” is any amino acid. The NZF type 
of zinc finger is a compact zinc-binding module found in many proteins that function in 
ubiquitin-related processes, including direct interaction with ubiquitins (Alam et al., 2004). 
The solution structure of the MDM2 C4 zinc finger (Protein Data Bank accession 2C6B) 
(Yu et al., 2006) indeed discloses that MDM2 shares the zinc finger structure with a wide 
variety of proteins that have distinct functions and mostly involve binding other 
macromolecules. For instance, the C4 zinc finger of RanBP2 binds to the nuclear export 
receptor protein Crm-1 (Singh et al., 1999). Also, the C4 zinc finger domain of some other 
proteins mediates binding to RNA. For example, the zinc finger protein znf265 interacts 
with pre-mRNA and is able to alter splicing patterns (Adams et al., 2001), and the zinc 
finger domain of Npl4 binds to ubiquitin (Alam et al., 2004; Meyer et al., 2002). Although 
the MDM2 zinc finger may not bind to ubiquitin (Meyer et al., 2002), it could directly bind 
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to rRNA, mRNA, or Crm-1, and if so, RPL11 (and other MDM2-binding RPs) might 
compete with MDM2 for binding to these molecules.
Consistent with the observation that RPL11, RPL5 and RPL23 bind to overlapping yet 
distinct domains within the central region of MDM2, these RPs appear to utilize similar yet 
non-identical mechanisms to regulate MDM2’s E3 ubiquitin ligase activity (Dai et al., 
2006b). Like ARF, when RPL11 is over expressed in cells, it suppresses p53 
polyubiquitination to a lesser degree than do RPL5 and RPL23 (Dai et al., 2006b). Also 
similar to ARF, RPL11 does not inhibit ubiquitination of Mdm2, instead it represses 
degradation of MDM2 via a postubiquitination mechanism, whereas RPL5 and RPL23 
suppress MDM2 autoubiquitination when co-expressed with MDM2 (Dai et al., 2006b). 
However, it remains intangible how exactly these RPs negate MDM2’s E3 ligase activity 
(see more discussion in the following section).
It is intriguing that all the MDM2-interacting RPs are important for p53’s full response to 
nucleolar stress. Why, then, are multiple RPs needed to interact with MDM2 and suppress 
its activity, and why does knockdown of each of the RPs attenuate, at least partially, 
nucleolar stress-induced p53 activation? Although there has not been a definitive answer 
thus far, it is possible that multiple RPs might sense different growth inhibitory or ribosomal 
stress signals so that different steps of ribosomal biogenesis can be effectively monitored. 
Also, in addition to the aforementioned difference in their mechanisms, the amino acid 
sequence in MDM2 required for RPL23 binding is different from that for RPL11 binding, so 
that RPL23 and RPL11 can bind MDM2 simultaneously to form a ternary complex (Dai et 
al., 2006b; Lindstrom et al., 2007b). Consistent with this idea, endogenous RPL23 and 
RPL11 appear to react differently to Actinomycin D treatment, as the former decreased 
whereas the latter increased when cells were treated with Actinomycin D (Jin et al., 2004). 
Moreover, multiple MDM2-binding RPs may work together to synergize their inhibitory 
effects on MDM2 when an error in ribosomal biogenesis occurs, as exemplified by the 
cooperation of RPL11 with RPL5 to synergistically inhibit MDM2 and activate p53 (Horn 
and Vousden, 2008). This is consistent with the finding that RPL11 and RPL5 are more 
essential for p53 response to nucleolar stress than is RPL23, as knockdown of RPL11 or 
RPL5 substantially alleviates p53 activation induced by this stress, whereas knockdown of 
RPL23 actually induces p53 (Dai et al., 2004; Jin et al., 2004). Another explanation for why 
multiple RPs may perform similar functions to activate p53 could be that they may 
compensate for one another or serve as rescuers if any of them fails. Because ribosomal 
biogenesis is a highly coordinated process involving a number of vital cellular activities 
taking place in different subcellular compartments and involving numerous steps and co-
factors, errors could occur at each of these steps and pose dire consequences for cells. To 
monitor these steps, each of the MDM2-interacting RPs may preferentially recognize 
specific signals of nucleolar stresses. In partial agreement with this hypothesis, knockdown 
of RPS6 impairs 40S ribosomal biogenesis, promotes the translation of RPL11 mRNA 
specifically, and subsequently initiates RPL11-dependent MDM2 inhibition and p53 
activation (Fumagalli et al., 2009). In summary, for cells to grow and proliferate normally, 
multiple RPs appear to be needed to signal to the p53 pathway in response to a variety of 
nucleolar stresses (Figure. 1).
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How do the ribosomal players work?
If multiple RPs are needed to sense and transduce nucleolar stress to the MDM2-p53 
pathway, then how do they work? Where do the RPs find and bind to MDM2, as RPs mostly 
reside in the nucleolus and the cytoplasm, while MDM2 often stays in the nucleoplasm? One 
possibility is that the RPs may interact with MDM2 in the nucleoplasm on their way to the 
nucleolus, as they, once translated in the cytoplasm, must be transported through the 
nucleoplasm to the nucleolus for Ribosome assembly. An increase in RP translation would 
lead to increased traffic of the RPs through the nucleus, consequently an increased 
interaction with MDM2. In this regard, the RP-MDM2 interaction could function as a 
mechanism sensing elevated RP translation, such as the increase in global translation caused 
by overexpression of the proto-oncogene c-Myc (Schmidt, 2004) or the rise of RPL11 level 
by RPS6 knockdown (Fumagalli et al., 2009). It could also sense the breakdown of 
cytoplasmic polysomes and the resulting release of individual ribosomal RPs into the 
nucleoplasm (Dai et al., 2004; Gilkes et al., 2006; Jin et al., 2004). Alternatively, given that 
there is not a physical boundary between the nucleoplasm and the nucleolus, RPs and other 
nucleolar proteins could shuttle freely between the two cellular compartments (Chen and 
Huang, 2001), which would provide an opportunity for excess RPs to interact with MDM2 
in the nucleoplasm. In a similar and reciprocal way, MDM2 may enter the nucleolus, as can 
be seen after cells treated by MG132 (Klibanov et al., 2001), presumably through its 
interaction with the nucleolar ARF (Tao and Levine, 1999; Weber et al., 1999), and thus 
interact with RPs in the nucleolus (Lohrum et al., 2003). However, the latter mechanism 
might be context specific, as MDM2 was not detected in the nucleolus under unstressed or 
nucleolar-stress conditions in recent studies (Dai et al., 2008; Sun et al., 2008).
Another quandary regarding how RPs regulate MDM2 concerns protein levels in a cell. 
Unlike DNA damage- or aberrant oncogene-induced p53 activation, which often requires 
either activation of a kinase (checkpoint kinases) or induction of a protein (the tumor 
suppressor ARF) that is usually maintained at basal levels under unstressed conditions, RPs 
are always abundant in cells. Then, how is the RP-MDM2 interaction prevented under 
normal and favorable growth conditions, yet promoted in response to nucleolar stress? It is 
conceivable that without stress, an appropriate amount of RPs is produced just for the need 
of Ribosome assembly, but any excess RPs beyond this demand undergo constant 
degradation (Lam et al., 2007). However, under nucleolar stress, rRNA synthesis is reduced 
or blocked and extra Ribosome-unbound RPL11 translocates to the nucleoplasm to interact 
with MDM2 and activate p53 (Bhat et al., 2004), even though the total amount of RPs is not 
altered.
As discussed above, like ARF, all MDM2-binding RPs inhibit the MDM2 ubiquitin ligase 
activity by binding to its central acidic domain. However, it is unclear how exactly the 
binding of these small inhibitory proteins in the middle of MDM2 leads to inhibition of the 
ubiquitin ligase activity of its C-terminal RING finger. One possible explanation is that the 
central acidic domain of MDM2 acts as a flexible arm to juxtapose the N-terminal-bound 
p53 within close proximity of the C-terminal RING domain in order to facilitate ubiquitin 
transfer. The binding of RPL11 or other small protein molecules to the MDM2 central 
domain may reduce its flexibility, and the rigid MDM2 is thus unable to bring its RING 
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domain and p53 together. Although this prediction is tempting, direct evidence is lacking 
and a better mechanistic insight will come from a three-dimensional structure of the 
complex of MDM2 with RPL11 or other RPs.
Another possible mechanism by which RPs inhibit MDM2’s E3 ligase activity concerns the 
MDM2 homologue MDMX. Previous studies using protein overexpression and siRNA 
knockdown suggested that MDMX enhances the MDM2 E3 ligase activity (Linares et al., 
2003). A later study showed that MDMX-deficient MEF cells (Mdm2+/−;MdmX−/−) had a 
moderately elevated level of endogenous p53 compared to that in MDMX-proficient cells 
(Mdm2+/−;MdmX+/+) (Francoz et al., 2006), suggesting that MDMX may contribute to p53 
degradation in vivo. Although how MDMX contributes to MDM2’s E3 activity remains 
obscure, it is clear that MDMX is essential for negating p53 function as germline 
inactivation of Mdmx results in embryonic lethality that can be rescued by concomitant 
deletion of p53 (Migliorini et al., 2002; Parant et al., 2001). The RING finger domain of 
MDMX is crucial for MDM2-mediated p53 degradation (Poyurovsky et al., 2007; Uldrijan 
et al., 2007), probably by facilitating heterodimerization with MDM2 (Jackson and 
Berberich, 2000; Sharp et al., 1999; Stad et al., 2000; Tanimura et al., 1999). Hence, it is 
possible that RPs (probably ARF as well) might inhibit MDM2 function by disrupting the 
MDM2-MDMX interaction. Alternatively, RPL11 can promote MDMX degradation by 
binding to MDM2, consequently activating p53, as it fails to do so when the RPL11 binding-
deficient MDM2C305S mutant is used (Gilkes et al., 2006).
In addition to mediating p53 ubiquitination, the C-terminal RING domain of MDM2 is 
shown to be the E3, at least in vitro, for its own ubiquitination and degradation (Fang et al., 
2000; Honda and Yasuda, 2000). However, even though ectopic RPL11 can inhibit MDM2-
mediated p53 ubiquitination, it does not inhibit MDM2 autoubiquitination (Dai et al., 
2006b), just like ARF (Xirodimas et al., 2001). Thus, it appears that these two small proteins 
preferentially inhibit MDM2’s E3 activity toward p53 but not its autoubiquitination. This 
could be explained by the existence of a putative cellular E3 ligasese for MDM2, as in vivo 
MDM2 bearing a C462A mutation in its C-terminal RING domain, which abolishes its E3 
ligase activity, is still ubiquitinated and degraded as quickly as wild type MDM2 under both 
unstressed and genotoxically stressed conditions (Itahana et al., 2007), which could also 
explain why RPL11 or ARF do not inhibit MDM2 “autoubiquitination” (Dai et al., 2006b).
Relevance to cancer and other genetic diseases
Identification of several RPs as crucial players in regulating p53 function not only reveals 
molecular insight into this under-appreciated signaling pathway but also raises new 
questions concerning the importance of RPs in cancer prevention and development. The role 
of RPs and ribosomal biogenesis in tumorigenesis has been regarded as a double-edged 
sword. On one hand, elevated levels of ribosomal biogenesis and protein translation, such as 
from overexpression of eIF-4E (Ruggero et al., 2004; Wendel et al., 2004) and tRNAs and 
5S rRNA (Marshall et al., 2008), have been linked to tumor formation in multiple mouse 
tissues [reviewed by (Dai and Lu, 2008; Ruggero and Pandolfi, 2003)]. For example, 
overexpression of RPS3a can lead to transformation and tumorigenesis in nude mice (Naora 
et al., 1998). On the other hand, reduction of ribosomal biogenesis and translational capacity 
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due to genetic hapoloinsufficiency, such as loss of one copy of an RP-encoding gene or 
mutation of a gene essential for ribosomal biogenesis, has been associated with a high 
incidence of cancer development in humans. For instance, mutation of the DKC1 gene, 
whose protein product dyskerin is a putative pseudouridine synthase important for pre-rRNA 
processing, is tightly linked to dyskeratosis congenital disease with characteristics of 
premature aging and an increased susceptibility to certain cancers (Ruggero et al., 2003). 
Also, RMRP, encoding an RNase vital for pre-rRNA processing, is mutated in the 
pleiotropic human disease Cartilage-Hair hypoplasia, which typically results in short stature, 
defective cellular immunity, and predisposition to cancer (Ridanpaa et al., 2001).
Mutations in several RPs have also been linked to cancer-prone genetic diseases. A 
prominent example is Diamond-Blackfan anemia (DBA), an inheritable disease initially 
found to be associated with mutation of RPS19. Heterozygous null mutations of RPS19 were 
found in 25% of DBA patients (Draptchinskaia et al., 1999), who often suffer chronic 
constitutional regenerative anemia, various degrees of congenital abnormalities, and an 
increased susceptibility to hematopoietic malignancies. Another RP-associated disease is 5q-
syndrome, which is frequently linked with deletion of one allele of RPS14 and characterized 
by increased incidence of hematopoietic tumors and anemia (Ebert et al., 2008). 
Remarkably, recent studies have found various heterozygous mutations, including single 
point mutations, in RPL5, RPL11, and RPS7 in DBA patients (Cmejla et al., 2009; Gazda et 
al., 2008). Mutational screening in zebrafish has also revealed a number of RP genes are 
cancer related (Amsterdam et al., 2004) and mutations of these genes in zebrafish are linked 
with growth impairment and predispoition to tumorigenesis (Lai et al., 2009). Although it is 
still unknown how mutations in the RPs result in DBA and cancer, the fact that RPL5, 
RPL11 and RPS7, three RPs mutated in DBA (Gazda et al., 2008), are all MDM2-binding 
proteins cannot be regarded as coincidence.
In addition to the association of RP mutants with DBA and cancer, mutations in RPS19 or 
RPS20 are also tied with a p53-mediated dark skin effect in mice (McGowan et al., 2008). It 
is perplexing how the reduction of a specific RP can cause a tissue- and cell-specific 
pathological phenotype. The pathological changes may result from global decline of 
ribosomal biogenesis owing to loss of one copy of an rp gene and subsequent diminution of 
translation (Ellis and Lipton, 2008; Liu and Ellis, 2006). It is also speculated that some of 
these diseases can be explained by RPL11-mediated deregulation of c-Myc, an important 
player in ribosomal biogenesis (Dai et al., 2007). A testable hypothesis is that 
haploinsufficiency of certain RPs could reduce the production of tumor suppressors, such as 
p53 (MacInnes et al., 2008), and hence render DBA patients more susceptible to 
tumorigenesis. Finally, it is postulated that the high incidence of malignancies in the RP-
pertinent diseases could be a result of a defect in the p53 pathway. As discussed above, 
several RPs including RPL11, RPL5, RPL23, and RPS7 can activate p53 by attenuating 
MDM2 function in response to stresses derived from ribosomal malfunction. Hence, it is 
possible that reduced expression of some RPs could impede stress-induced p53 activation 
due to their decreased MDM2 interaction.
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Questions and prospects
Although accumulating evidence has begun to divulge a relatively new signaling pathway 
linking defects in ribosomal biogenesis with p53, suggesting another cellular surveillance 
mechanism for cancer prevention, more questions than answers are brought up by these 
studies. (1) Why are multiple RPs needed to signal to p53? So far, there are at least 4 
confirmed RPs that bind to the central acidic domain of MDM2 and utilize apparently 
similar mechanisms to activate p53. Do multiple RPs have redundant roles, inhibiting 
MDM2 in response to the same type of stress? Or, do they have specific roles in sensing 
different types of stress? (2) What are the physiological stresses that activate the RP-p53 
signaling pathway? Would cancer develop if this pathway were impaired? A mouse model 
that specifically targets this pathway is crucial for understanding the physiological role of 
the RP-MDM2 interaction. (3) Does Mdm2 have a general role in regulating RP turnover, 
like that shown for RPL26 and RPS7 (Ofir-Rosenfeld et al., 2008; Zhu et al., 2009)? If so, 
would this explain MDM2 overexpression-induced growth inhibition? (4) Do the MDM2-
interacting RPs signal to p53 in response to rRNA damage? rRNAs are the most actively 
synthesized nucleic acid species in a cell, highly abundant and essential for cell growth and 
proliferation (Neufeld and Edgar, 1998; Warner, 1999). Thus, rRNA is vulnerable to both 
endogenous and exogenous genotoxic agents. A recent study showed that yeast utilizes 
similar mechanisms to repair genotoxic damage to both DNA and rRNA molecules (Fujii et 
al., 2009). How the integrity of rRNA is monitored during ribosomal biogenesis is not clear, 
nor do we know how p53 may sense rRNA damage. (5) Are any of RPs mutated in human 
cancers? As discussed above, mutations in RPL5 and RPL11 are associated with DBA 
(Cmejla et al., 2009; Gazda et al., 2008). Reports of direct connections between mutations in 
the p53-activating RPs and cancer, however, have been lacking. It is possible that these RPs 
may play a role in cancer in a manner similar to the so-called non-oncogene addiction 
(NOA) molecules (Luo et al., 2009; Solimini et al., 2007). Unlike oncoproteins, such as H-
Ras or c-Myc that are often mutated in human cancers, NOA proteins are rarely mutated in 
human cancers. However, like oncoproteins, NOA proteins are required for cancer cell 
growth. Under normal growth conditions, the p53-activating RPs are essential components 
of Ribosome biogenesis. Under stress conditions, their intrinsic anti-tumor activities are 
awakened (Figure 1). Examples of other proteins that are crucial for p53 activation but are 
not normally mutated in cancers include Chk1, Chk2, p300, and CBP. The intrinsic anti-
tumor activities of these molecules could be useful for anti-cancer drug discovery (Luo et 
al., 2009).
Indeed, identification of MDM2-RP interactions offers an opportunity for anti-cancer drug 
development. MDM2 is highly expressed in various human cancers, including breast cancer, 
sarcoma, glioma, and blood cancers [reviewed in (Onel and Cordon-Cardo, 2004)]. MDM2 
is amplified in about 50% of leukemias and lymphomas, in which TP53 mutations are rare 
(Bueso-Ramos et al., 1996). Hence, MDM2 could be an ideal target for anti-cancer drugs. 
The previous focus of anti-MDM2 drug screening has been on either the N-terminal p53-
binding domain (Issaeva et al., 2004; Shangary et al., 2008; Vassilev et al., 2004) or the C-
terminal RING-finger E3 ubiquitin ligase domain (Yang et al., 2005) of MDM2. The 
MDM2 central acidic domain, including the zinc finger, is crucial for MDM2-induced p53 
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ubiquitination and degradation (Kawai et al., 2003). The interaction of ARF and RPs with 
this MDM2 domain suppresses MDM2’s E3 activity and activates p53. Thus, the central 
domain represents another targeting site in MDM2 for anti-cancer drug screening. Future 
efforts should be taken to identify small molecules that inhibit MDM2 activity by directly 
binding to its central domain. Gaining promising candidates from this attempt will not only 
shed light on the biological significance of RP-MDM2-p53 interplay, but also provide 
potential drugs for therapeutic intervention of cancers that harbor wild type p53 and high 
levels of MDM2.
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Figure 1. Schematic of RP-MDM2-p53 pathway regulation by nucleolar stress
Under normal growth conditions (no stress), small (S, 40S) and large (L, 60S) RPs are 
assembled in the nucleolus (NO) and transported to the cytoplasm (CP) for protein 
synthesis. Under nucleolar stress, ribosomal biogenesis is inhibited and Ribosome-free 
forms of RPs (RPL and RPS) enter the nucleoplasm (NP) to interact with MDM2, resulting 
in p53 stabilization and activation. Similarly, RPs either released from breaking down 
(indicated by wavy edges) of cytoplasmic Ribosomes or overproduced in the cytoplasm can 
enter the nucleoplasm to interact with MDM2.
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